FDA adds boxed warning of increased severe hypocalcemia risk for denosumab

The FDA has added a boxed warning for denosumab to advise patients with advanced chronic kidney disease of an increased risk for severe hypocalcemia, according to an FDA drug safety communication.
On Jan. 19, the FDA said it had concluded that denosumab (Prolia, Amgen) increases the risk for severe hypocalcemia for people with advanced CKD, particularly those on dialysis. The announcement came less than 2 months after the agency announced in November that it would be investigating the risk for severe hypocalcemia among people receiving denosumab. The drug safety communication was issued after

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart
This website uses cookies and asks your personal data to enhance your browsing experience.